Buscar resultados de ensayos clínicos

Patrocinado por

Hematologic Neoplasms - 25 Studies Found

Estado Estudiar
Recruiting Nombre del estudio: A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
Condición: Hematologic Neoplasms
Fecha: 2015-02-13
Intervenciones:
  • Drug: CC-90002
  • Drug: Rituximab
Recruiting Nombre del estudio: Phase I Trial of BAY1251152 for Advanced Blood Cancers
Condición: Hematologic Neoplasms
Fecha: 2016-04-18
Intervenciones: Drug: BAY1251152 Weekly infusion of BAY1251152 in 21-day cycles.
Completed Nombre del estudio: Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.
Condición: Hematologic Neoplasms
Fecha: 2006-10-16
Intervenciones: Drug: CPX-351 (Cytarabine:Daunorubicin) Liposome Injection
Completed Nombre del estudio: Biomarker Research for Personalized Medicine
Condición: Hematologic Neoplasms
Fecha: 2011-12-06
Completed Nombre del estudio: A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
Condición: Hematologic Neoplasms
Fecha: 2008-02-18
Intervenciones: Drug: RO5045337 Multiple ascending doses
Terminated Nombre del estudio: A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
Condición: Haematological Malignancies
Fecha: 2010-03-02
Intervenciones:
  • Drug: AS703569

Active, not recruiting Nombre del estudio: Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condición: Hematologic Neoplasms
Fecha: 2013-02-26
Intervenciones: Drug: Panobinostat single agent panobinostat starting with last assigned dose and regimen which patient
Active, not recruiting Nombre del estudio: Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies
Condición:
  • High Risk Haematological Malignancies
  • Advanced Hematologic Neoplasms
    Fecha: 2014-12-30
    Intervenciones:
    • Drug: Ibrutinib Participants w
Recruiting Nombre del estudio: Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation
Condición: Haematological Malignancy
Fecha: 2017-05-07
Intervenciones: Drug: Nivolumab Injection Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface rec
Next >>>